Found 365 clinical trials
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has the CAIX protein.
- 0 views
- 24 Mar, 2022
- 5 locations
Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY)
The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1/Modi-1v vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab (where these are standard of care in a non-neoadjuvant setting), in patients with …
- 0 views
- 26 May, 2022
- 3 locations
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood
- 0 views
- 07 Aug, 2021
- 3 locations
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
This phase I trial studies the side effects and best dose of aldesleukin when given together with pembrolizumab in treating patients with kidney cancer that has spread to other parts of the body
- 21 views
- 13 Apr, 2022
- 1 location
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition (Cyto-KIK)
without any visible kidney cancer in their body at some point during the course of treatment.
- 42 views
- 22 Apr, 2022
- 2 locations
Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation (PERFORM)
Cancer immunotherapy has been largely adopted in oncology patient management in the last decade. The deep and long responses to immunotherapy have accelerated the approval of these drugs across multiple disease sites. However, these agents can also be toxic to patients, meaning, the patient will have to discontinue treatment and …
- 22 views
- 23 Apr, 2022
- 1 location
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
and temozolomide may help treat patients with hereditary leiomyomatosis and renal cell cancer.
- 0 views
- 04 Nov, 2021
- 1 location
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer
- 114 views
- 27 May, 2022
- 4 locations
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO)
The NESCIO-trial is a multicenter, randomized, open-label, three-arm phase II trial investigating different combinations of neoadjuvant immunotherapy in patients with primary, resectable, intermediate to high-risk, clear-cell renal cell carcinoma. In this trial patients will be randomized 1:1:1 to receive either 2 cycles of nivolumab 360mg every 3 weeks (arm A), …
- 0 views
- 24 May, 2022
- 1 location
Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with advanced/metastatic renal cell carcinoma, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- 0 views
- 11 Jul, 2022
- 1 location